Stimulant Abuser Groups to Engage in 12-Step (STAGE-12)
Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32211
- Gateway Community Services
-
-
Hawaii
-
Kaneohe, Hawaii, United States, 96744
- Hina Mauka Kaneohe Rehabilitation Services
-
-
Ohio
-
Columbus, Ohio, United States, 43207
- Maryhaven, Inc.
-
-
Oregon
-
Eugene, Oregon, United States, 97402
- Willamette Family Treatment Services
-
Portland, Oregon, United States, 97233
- ChangePoint, Inc.
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Addiction Medicine Services (WPIC)
-
-
South Carolina
-
Summerville, South Carolina, United States, 29483
- Dorchester Alcohol and Drug Commission
-
-
Texas
-
Dallas, Texas, United States, 75228
- Nexus Recovery Center
-
-
Washington
-
Everett, Washington, United States, 98134
- Evergreen Manor, Inc.
-
Seattle, Washington, United States, 98122
- Recovery Centers of King County
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- seeking outpatient treatment for stimulant abuse or dependence
- current diagnosis of stimulant abuse or dependence
- willing to participate in the protocol
Exclusion Criteria:
- not sufficiently medically or psychiatrically stable
- pending legal action that would inhibit their participation in the study
- in need of detoxification from opiates
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: STAGE-12
STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers.
These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
|
The STAGE-12 intervention will consist of a combination of five group and three individual sessions.
The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format.
The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
|
|
Active Comparator: Treatment as Usual
Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Days of Stimulant Use
Time Frame: 6 months
|
Number of days of use of stimulant drugs within 30-day blocks across a 6-month post-baseline period
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Attendance at 12-step Meetings
Time Frame: 6 months
|
Days of attendance at 12-step meetings within 30-day blocks across a 6-month post-baseline period
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dennis Donovan, Ph.D., University of Washington
- Principal Investigator: Dennis Daley, Ph.D., Western Psychiatric Institute and Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIDA-CTN-0031
- U10DA013714 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.